Accessibility Menu
PhaseRx logo

PhaseRx(OTC) PZRXQ

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)-100%
5 Year-100%
1 Year+0%
1 Month+0%
$0.00
+0%
+0.00Today
PhaseRx last closing stock price
MetricPriceDate
Last closeUSD 0.002025-12-10
PhaseRx stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002025-11-05
1 month+0%USD 0.002025-11-05
3 month-99%USD 0.002025-08-08
Year to date+0%USD 0.002024-08-12
1 year+0%USD 0.002024-08-12
3 year-99%USD 0.002022-10-13
5 year-99.96%USD 0.002020-12-10
Since inception-100%USD 5.022016-05-18

PhaseRx Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$13.89M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

43.28 (High)

Price

$0.00

Volume

12,800

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

PZRXQ News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About PhaseRx

PhaseRx, Inc. is a biopharmaceutical company focused on developing innovative treatments for inherited enzyme deficiencies affecting the liver. Utilizing a unique Hybrid mRNA technology platform, the company aims to facilitate intracellular enzyme replacement therapy.

Products and Services
  • PRX-OTC targets ornithine transcarbamylase deficiency
  • PRX-ASL addresses argininosuccinate lyase deficiency
  • PRX-ASS1 focuses on argininosuccinate synthetase deficiency
Growth Outlook
  • Strong pipeline with multiple programs targeting urea cycle disorders
  • Established in 2006, with a solid foundation in biotechnology
  • Headquartered in Seattle, a hub for biopharmaceutical innovation
Financial Highlights
  • Recent quarterly net income of -$2.75 million
  • Cash and short-term investments totaled $5.26 million as of Q3 2017
  • Current ratio of 7.99 indicates strong liquidity position
PhaseRx, Inc. is dedicated to addressing critical health challenges through its innovative therapeutic strategies. The company's focus on enzyme replacement therapy positions it uniquely within the biotechnology sector. With a robust pipeline targeting specific genetic disorders, PhaseRx aims to make significant advancements in treatment options for patients with rare diseases. The financial data reflects ongoing investments in research and development, essential for driving future growth and innovation. The liquidity position, as indicated by the current ratio, suggests that the company is well-equipped to manage its operational needs while pursuing its strategic objectives.
AI Generated • Jul 6, 2026

Industry

Biotechnology

Headquarters

Seattle, WA 98119, US

PZRXQ Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

101.72%

Return on Capital

-122.20%

Return on Assets

-122.43%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

11.69M

Volume

12.80K

Avg. Volume

0

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$13.04M

EBITDA

-$12.87M

Operating Cash Flow

-$12.82M

Capital Expenditure

-$14.00K

Free Cash Flow

-$12.84M

Cash & ST Invst.

$5.26M

Total Debt

$5.44M

PhaseRx Performance Analysis

PhaseRx sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42016-12-31N/A
Q12017-03-31N/A
Q22017-06-30N/A
Q32017-09-30N/A
PhaseRx sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42016-12-31-3.4%
Q12017-03-31-16.7%
Q22017-06-3014.3%
Q32017-09-3020.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q3 2017YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

10

N/A

Net Income

-$2.75M

+17.7%

EBITDA

-$2.50M

+19.0%

Quarterly Fundamentals

Name
Q3 2017YOY CHG

Total Cash

$5.26M

-71.8%

Total Debt

$5.44M

-3.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$3.61M

-35.6%

Short Term Debt

$1.83M

N/A

Return on Assets

-1.22%

N/A

Return on Invested Capital

-1.27%

N/A

Free Cash Flow

-$2.57M

-0.7%

Operating Cash Flow

-$2.57M

-0.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
COTQFCotinga Pharmaceuticals Inc.
$0.00+0.00%
OVITOncoVista Innovative Therapies, Inc.
$0.00+0.00%
ANTHAnthera Pharmaceuticals, Inc.
$0.00+0.00%
LPTILongport, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%
TQQQProShares Trust - ProShares UltraPro Qqq
$63.40-0.01%

Questions About PZRXQ

What is the current price of PhaseRx?

PhaseRx is trading at $0.00 per share.

What is the 52-week range for PhaseRx?

Over the past 52 weeks, PhaseRx has traded between $0.00 and $0.00.

How much debt does PhaseRx have?

PhaseRx total debt is unavailable.

How much cash does PhaseRx have on hand?

PhaseRx does not have cash on hand data available.

What is PhaseRx’s dividend yield?

PhaseRx does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.